Involvement of FSP1-CoQ_{10}-NADH and GSH-GPx-4 pathways in retinal pigment epithelium ferroptosis

Ming Yang, Michelle Grace Tsui, Jessica Kwan Wun Tsang, Rajesh Kumar Goit, Kwok-Ming Yao, Kwok-Fai So, Wai-Ching Lam and Amy Cheuk Yin Lo

© The Author(s) 2022, corrected publication 2024

Retinal pigment epithelium (RPE) degeneration plays an important role in a group of retinal disorders such as retinal degeneration (RD) and age-related macular degeneration (AMD). The mechanism of RPE cell death is not yet fully elucidated. Ferroptosis, a novel regulated cell death pathway, participates in cancer and several neurodegenerative diseases. Glutathione peroxidase 4 (GPx-4) and ferroptosis suppressor protein 1 (FSP1) have been proposed to be two main regulators of ferroptosis in these diseases; yet, their roles in RPE degeneration remain elusive. Here, we report that both FSP1-CoQ_{10}-NADH and GSH-GPx-4 pathways inhibit retinal ferroptosis in sodium iodate (SIO)-induced retinal degeneration pathologies in human primary RPE cells (HRPEpiC), ARPE-19 cell line, and mice. GSH-GPx-4 signaling was compromised after a toxic injury caused by SIO, which was aggravated by silencing GPx-4, and ferroptosis inhibitors robustly protected RPE cells from the challenge. Interestingly, while inhibition of FSP1 caused RPE cell death, which was aggravated by SIO exposure, overexpression of FSP1 effectively protected RPE cells from SIO-induced injury, accompanied by a significant down-regulation of CoQ_{10}/NADH and lipid peroxidation. Most importantly, in vivo results showed that Ferrostatin-1 not only remarkably alleviated SIO-induced RPE cell loss, photoreceptor death, and retinal dysfunction but also significantly ameliorated the compromised GSH-GPx-4 and FSP1-CoQ_{10}-NADH signaling in RPE cells isolated from SIO-induced RPE degeneration. These data describe a distinct role for ferroptosis in controlling RPE cell death in vitro and in vivo and may provide a new avenue for identifying treatment targets for RPE degeneration.

Cell Death and Disease (2022)13:468 ; https://doi.org/10.1038/s41419-022-04924-4

INTRODUCTION

Retinal pigment epithelium (RPE) is a single layer of pigment cells that lies between the neural retina and choroid. It consists of ~5 million hexagonal RPE cells attaching to its basal lamina (Bruch’s membrane) [1]. RPE degeneration plays an important role in a range of retinal disorders such as retinal degeneration and age-related macular degeneration [2]. oxidative stress is considered a key mechanism for RPE degeneration [3, 4]. The imbalance between the oxidation and antioxidation systems in the retina increases the production of highly reactive molecular oxygen free radicals (ROS) and nitrogen free radicals, which in turn leads to RPE degeneration [4–6].

The process of cell death has been considered unregulated until the concept of programmed cell death (PCD) was proposed [7]. Nowadays, cell death is classified into two categories: accidental cell death and regulated cell death (RCD) [8]. Despite previous studies on retina cell damage associated with oxidative stress [4, 9, 10], retina cell death mechanisms are still not fully understood. Many agents have been used to induce retinal cell death, one of which is sodium iodate (SIO), an oxidizer that is toxic to RPE and neuroretina, making it a suitable model for RPE degeneration [11–13]. There has been one report on necroptosis-associated RPE injury after SIO treatment; [14] yet, the cell death mechanism of SIO-mediated RPE damage is still not fully elucidated.

Ferroptosis was first proposed in 2012 by Dixon et al. [15]. It is an iron-dependent and non-apoptotic cell death, with distinctive features including iron overload, lipid peroxidation, and mitochondrial destruction [16]. Current research has classified ferroptosis into several pathways: (1) depletion of glutathione (GSH), with a decreased activity of GPx-4 (GSH-GPx-4 pathway) [15, 16]; (2) GTP cyclohydrolase-1 (GCH1) and tetrahydrobiopterin/dihydriobiopterin (BH4/BH2). BH4 and BH2 are metabolic derivatives of GCH1, which contribute to lipid remodeling and ferroptosis suppression [17]; and (3) decreased activity of ferroptosis suppressor protein 1 (FSP1), accompanied by the exhaustion of CoQ_{10} (FSP1-CoQ_{10}-NADH pathway) [18, 19].

Besides the discovery of hydrogen-peroxide-associated RPE ferroptosis [20], little is known about SIO-induced ferroptosis in primary human RPE cells and in vivo. This study aimed to elucidate the role of ferroptosis in SIO-induced RPE degeneration in vitro and in vivo models using gain of function and loss of function strategies. The characterization of ferroptosis involvement in RPE degeneration pathogenesis will aid the search for treatment targets for RPE degeneration.
RESULTS
SIO-induced RPE death mimics RPE degeneration in vitro and in vivo
To determine the optimal SIO concentration for inducing RPE cell death, primary HRPEpiC and ARPE-19 cells were exposed to SIO at 0, 0.1, 1, 5, 10, 20 mM for 24 h, respectively (Fig. 1A). Primary HRPEpiC cells showed significant morphological changes after the 10 mM SIO challenge, displaying ruptured cell membrane and cell debris as well as a significant decrease in cell density (Fig. 1B). Similar results were obtained in ARPE-19 cells (Fig. 1C).
Cell Counting Kit-8 (CCK-8) assay showed that SIO decreased primary HRPEpiC cell viability in a dose-dependent manner, with only around 15% of cells surviving at 20 mM SIO (p < 0.001, Fig. 1D). In contrast, ARPE-19 cells were more resistant; cell viability was around 50% at 20 mM SIO (Fig. 1E). We selected the dosages (10 and 20 mM) that cause around 50% cell death in primary HRPEpiC and ARPE-19 cells, respectively for further studies.

The doses of ferrostatin-1 (Fer-1) and deferoxamine (DFO) (two inhibitors of ferroptosis) were also optimized in SIO-treated primary HRPEpiC and ARPE-19 cells. Primary HRPEpiC cell viability increased with Fer-1 or DFO treatment, reaching a maximum of 77.45% for Fer-1 (50 µM) and 73.92% for DFO (25 µM) (p < 0.001, Fig. 1F, G). Similar results were obtained for ARPE-19 (Fig. 1H, I). Therefore, Fer-1 (50 µM) and DFO (25 µM) were selected for subsequent studies.

Intraperitoneal SIO injection (30 or 50 mg/kg) in mice was performed to establish the RPE degeneration in vivo model as described previously [21]. Electroretinogram (ERG) is used to test the electrical activity and responsiveness of the retina upon light stimulation [22]. It represents the physiological health of the retina. The waveforms generated are separated into two components: a-wave followed by b-wave. The a-wave is generated by the photoreceptor while b-wave reflects the response from the bipolar cells and other layers of the outer retina. ERG was therefore measured as reported [23–26] to reflect retinal function. ERG showed that there were significant decreases in both a- and b-wave amplitudes 3 days after SIO administration, indicating the successful establishment of the model (Fig. 1J, p < 0.001). In this study, we, therefore, selected a single intraperitoneal injection of SIO (30 mg/kg) for 3 days as the in vivo model for RPE degeneration.

Ferroptosis regulates SIO-induced cell death in RPE cells by GSH-GPx-4 pathway

To investigate the role of ferroptosis in primary HRPEpiC cell death induced by SIO, Fer-1, and DFO, two classical ferroptosis inhibitors were used. Initially, 10 mM SIO significantly induced cell damage and reduced cell viability (Fig. 2A, B, p < 0.001). LIVE/DEAD cell imaging assay also showed increased red signals, indicating cell death with a decreased live-cell green signal (Fig. 2A). However, cells pre-treated with 50 µM Fer-1 for 3 h showed less damage with higher cell viability and fewer red signals, indicating that Fer-1 rescued SIO-induced primary HRPEpiC cell death (Fig. 2A). Meanwhile, primary HRPEpiC cells after 25 µM DFO pre-treatment displayed decreased cell death and morphological changes upon SIO stress (Fig. 2C, D). These results suggested that ferroptosis is involved in SIO-induced primary HRPEpiC cell death.

To further understand how ferroptosis mediated primary HRPEpiC cell death upon SIO exposure, intracellular iron level, glutathione metabolism, GPx-4 expression, and lipid peroxidation were assayed. As shown in Fig. 2E, SIO significantly increased intracellular labile iron level, which was reduced with 3 h of iron chelator DFO pre-treatment. In addition, while intracellular total GSH (Fig. 2F, p < 0.001), GSH/GSSG (Fig. 2G, p < 0.001), and GSH (Fig. 2H, p < 0.001) showed a remarkable decrease upon SIO exposure, GSSG level was significantly increased (Fig. 2I), indicating exhaustion of glutathione metabolism. However, DFO pre-treatment alleviated this change, suggesting the involvement of GSH signaling in SIO-induced primary HRPEpiC ferroptosis.

Next, the expression of GPx-4, the key enzyme in glutathione metabolism and ferroptosis [27] was measured. A significant decrease of GPx-4 expression upon SIO stress was observed, and this was mitigated by pre-treatment with DFO (Fig. 2J, K, p < 0.001). We further assessed the level of long-chain-fatty-acid-CoA ligase 4 (ACSL-4), one of the key enzymes contributing to lipid peroxidation and malondialdehyde (MDA), a marker of lipid peroxidation. The results showed that SIO significantly elevated both ACSL-4 expression (Fig. 2L, M, p < 0.001) and MDA level (Fig. 2N, p < 0.001), but these were attenuated by Fer-1 pre-treatment (p < 0.001). To further confirm this, we also tested DFO, another ferroptosis inhibitor that elicited a similar decrease in MDA level (Fig. 2O, p < 0.001). As GPx-4 is the key regulator of the classical ferroptosis pathway, we also adopted a loss-of-function strategy, i.e., GPx-4 siRNA transfection assay to further confirm the role of ferroptosis in SIO-induced cell death. SIO significantly increased the immunofluorescence intensity of 4-Hydroxynonenal (4-HNE) and this up-regulation was stronger in primary HRPEpiC cells transfected with GPx-4 siRNA (Fig. 5A, B, p < 0.001). In addition, transmission electron microscopy (TEM) showed typical ferroptosis-related morphological features in SIO-induced primary HRPEpiC cells; decreased mitochondria size with increased membrane density were observed. These mitochondrial morphological changes were more apparent in GPx-4 knockdown cells compared with control (Fig. S1C). These data suggested that ferroptosis in primary HRPEpiC cells induced by SIO is mediated through the GSH-GPx-4 pathway.

Using the same pharmacological strategies, we also studied the role of SIO-induced ferroptosis in ARPE-19 cells. Consistently, SIO drastically decreased ARPE-19 cell viability but this was significantly ameliorated by 50 µM Fer-1 (Fig. S2A, B) or 25 µM DFO pre-treatment for 3 h (Fig. S2C, E), suggesting that Fer-1 and DFO protect against SIO-induced ARPE-19 cell death. Cell morphology, cell viability, intracellular iron level, glutathione metabolism, GPx-4 expression, and lipid peroxidation were further assayed in SIO-challenged ARPE-19 cells. The results were similar to those observed in primary HRPEpiC cells (Fig. S2A–K). Most importantly, ARPE-19 cells transfected with GPx-4 siRNA showed more significant morphological damage and reduced cell viability.
There was a further increase in red signals in the LIVE/DEAD cell imaging assay, indicating that enhancement of ferroptotic activity aggravated SIO-induced cell death (Fig. S2O, R). In addition, SIO significantly increased the immunofluorescence intensity of 4-HNE and this up-regulation was stronger in cells transfected with GPx-4 siRNA (Fig. S2Q, p < 0.001). Furthermore, GPx-4 siRNA transfected cells showed more significantly damaged cell morphology, and reduced cell viability with further increased red signals, indicating that enhancing the activity of ferroptosis by reduction of GPx-4 levels aggravated SIO-induced cell death (Fig. S2R). Moreover, TEM revealed...
Ferroptosis regulates SIO-induced human primary HRPEpiC cell death. Fer-1 (50 µM) or its vehicle (0.14% DMSO) was added to human primary HRPEpiC cells for 3 h before control (PBS) or SIO (10 mM) treatment. DFO (25 µM) or its vehicle (PBS) was added to human primary HRPEpiC cells 3 h before control (PBS) or SIO (10 mM) treatment. A Phase-contrast and fluorescence microscope images of cell morphology and Live/dead cell staining of SIO-exposed human primary HRPEpiC cells with/without Fer-1 pre-treatment are shown. Scale bar = 100 µm. B CCK-8 cell viability assay results of the effect of Fer-1 on 10 mM SIO-induced human primary HRPEpiC cell death. n = 4 (independent experiments). C CCK-8 cell viability assay results of the effect of DFO on 10 mM SIO-induced human primary HRPEpiC cell death. n = 4 (independent experiments). D Phase-contrast and fluorescence microscope images of cell morphology and Live/dead cell staining of SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment are shown. Scale bar = 100 µm. n = 4 (independent experiments). E Labile iron levels in SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment. n = 4 independent experiments. F Total GSH level of SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment. n = 4 (independent experiments). G GSSG level of SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment. n = 4 (independent experiments). H GSH level of SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment. n = 4 (independent experiments). I GSH/GSSG ratio of SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment. n = 4 (independent experiments). J The expression of GPx-4 of SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment showed by Western blot. K Quantitative analysis of the expression of GPx-4. n = 4 (independent experiments). L The expression of ACSL-4 of SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment showed by Western blot. M Quantitative analysis of the expression of ACSL-4. n = 3 (independent experiments). N MDA level of SIO-exposed human primary HRPEpiC cells with/without Fer-1 pre-treatment. n = 4 (independent experiments). O MDA level of SIO-exposed human primary HRPEpiC cells with/without DFO pre-treatment. n = 4 (independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001.

To further confirm the role of FSP1 in SIO-induced ARPE-19 cell death, the expression of FSP1 was performed. ARPE-19 cells were transfected with FSP1 DNA plasmid or vector control DNA for 48 h and subjected to SIO at different concentrations 0, 1, 2.5, 5, 10, 25, 50 µM.

M. Yang et al.

Cell Death and Disease (2022) 13:468

SPRINGER NATURE

dense and shrunken mitochondria in SIO-exposed ARPE-19 cells, which were aggravated upon GPx-4 knockdown (Fig. S2S). These data suggest that GSH-GPx-4 pathway regulates ferroptosis in SIO-induced ARPE-19 cell damage.

Fer-1 significantly improved retinal function in the SIO-induced RPE degeneration model in vivo

To investigate the effect of Fer-1 on SIO-induced RPE cell death in vivo, we monitored survival rate, body weight, intracellular pressure, and retinal function in SIO-injected mice with/without Fer-1 treatment (Fig. 3A, B). As shown in Fig. 3C, there was no change in survival rate among SIO-challenged, Fer-1-treated, and vehicle controls throughout the 14 days of treatment. There was a slight increase in body weight in all 3 groups (Fig. 3D). No difference in intracellular pressure (IOP) could be observed among the three groups (Fig. 3E). However, SIO significantly decreased the amplitudes of ERG a-wave and b-wave in both eyes when tested at 3 and 10 cd s/m², which were subsequently rescued after 14 days of Fer-1 treatment for 14 days (Fig. 3F-H, p < 0.001). These data not only showed the protective effect of Fer-1 on SIO-induced retinal function loss in the RPE degeneration mouse model but also suggested the potential therapeutic role of ferroptosis in RPE degeneration.

Ferroptosis is involved in SIO-induced RPE degeneration in vivo

To confirm the involvement of ferroptosis in the SIO-induced RPE degeneration mouse model, mouse eyeballs were collected, sectioned, and analyzed. Cytoarchitectural evaluation on hematoxylin-and-eosin (H&E)-stained retinal sections showed that SIO significantly decreased retinal thickness and caused massive RPE cell loss (Fig. 4A). However, the Fer-1 treatment rescued the retina; it not only restored retinal thickness and rescued RPE cells (Fig. 4C-E, p < 0.001) but also protected the photoreceptor outer segments (Fig. 4F-H, p < 0.001). Meanwhile, there was also a significant increase in intracellular iron in isolated RPE cells from mouse retina after the SIO challenge, suggesting that labile iron was increased in vivo; yet, the iron overload in RPE was alleviated after Fer-1 treatment for 14 days (Fig. 4I, p < 0.001). Moreover, the GSH level in RPE was significantly decreased after the SIO challenge; but Fer-1 treatment again rescued the pathological change and restored the RPE GSH level (Fig. 4J, p < 0.001). To test for the presence of lipid peroxidation, we measured MDA levels in RPE. As shown in Fig. 4K, the SIO challenge induced an apparent increase in MDA level. However, this was significantly suppressed by 14 days of Fer-1 treatment. Taken together, these data supported the involvement of ferroptosis in the SIO-induced RPE degeneration model in vivo.

FSP1-CoQ10-NADH may also be involved in SIO-induced ferroptosis

To evaluate the role of FSP1 in SIO-induced ferroptosis, we performed pharmacological and gain-of-function experiments on ARPE-19 cells. As shown in Fig. 5A, a dose-dependent drop in cell viability was observed in ARPE-19 cells treated with iFSP1 (blue line). Fer-1 was able to reduce the decreased cell viability at all iFSP1 dosages tested (green line), suggesting that iFSP1 induces cell death via ferroptosis that can be blocked by Fer-1. SIO treatment on cells incubated with iFSP1 further decreased cell viability (black line). Most importantly, Fer-1 could again significantly reduce the decrease in cell viability caused by both SIO and iFSP1 administration in a dose-dependent manner (red line).

These findings are consistent with other studies showing the effect of iFSP1 is compromised by the treatment addition of ferroptosis inhibitors such as Fer-1 [28] and liproxstatin-1 [18]. Control normalization for SIO and iFSP1 was also performed to eliminate the possibility of a vehicle effect (Fig. S3A). As expected, no significant cell viability change was observed when there was an increased concentration of DMSO present in the 20 mM SIO-treated cells. Moreover, the effect of iFSP1 on SIO dose-response was tested. As shown in Fig. 5B-H, the slopes of SIO dose-response with 1 µM iFSP1 (n = 3) were not statistically different from those in the vehicle control group (p = 0.525, n = 3, Levene’s test), suggesting that the dose-response of ARPE-19 cells to SIO challenge in the presence of 1 µM iFSP1 was similar to that with vehicle treatment and iFSP1 caused no sensitization of SIO dose-response. To further confirm the role of FSP1, we chose iFSP1 at a dose of 5 µM, which induced the most significant effect on cell death for further studies. SIO administration significantly decreased cell viability with decreased cell density (Fig. 5B) and noticeable morphological changes (Fig. 5C) compared with the control group. iFSP1 further aggravated these effects, suggesting that FSP1 is required in SIO-induced ARPE-19 ferroptosis. In addition, intracellular NADH level was significantly decreased by SIO treatment but it was increased by iFSP1 administration (Fig. 5D). In contrast, SIO significantly elevated NAD+/NADH, which was ameliorated with iFSP1 treatment (Fig. 5E), suggesting that FSP1 might consume NADH in ARPE-19 cells. CoQ10 ELISA assay (Fig. 5F) also showed similar results as in the NADH assay. Furthermore, SIO not only significantly decreased the expression of FSP1 but also aggravated the increased fluorescence signal of 4-HNE induced by iFSP1, suggesting intensified lipid peroxidation activity in ARPE-19 cells (Fig. 5G, I).

To further confirm the role of FSP1 in SIO-induced ARPE-19 cell death, overexpression of FSP1 was performed. ARPE-19 cells were transfected with FSP1 DNA plasmid or vector control DNA for 48 h and subjected to SIO at different concentrations 0, 1, 2.5, 5, 10, 25, 50 µM.

4-HNE induced by iFSP1, suggesting intensified lipid peroxidation activity in ARPE-19 cells (Fig. 5G, I).
Fig. 3  A study design for assessment of the effect of Fer-1 on SIO-induced RPE degeneration in vivo. A Timeline of the study. On day 3, mice received a single intraperitoneal injection of SIO (30 mg/kg). On day 0, RPE degeneration phenotype was established at which daily treatment with Ferrostatin-1 (Fer-1) commenced and lasted for 14 days. The effect of Fer-1 in SIO-challenged mice was evaluated on day 14. B A schematic diagram showing ERG experimental procedures in mice. C Survival rate monitoring of mice receiving SIO and/or Fer-1 injections. D Body weight monitoring of mice receiving vehicle, SIO and/or Fer-1 injections. E Intraocular pressure in mouse eyes after SIO and/or Fer-1 treatment on day 14. n = 6 (biological replicates). n.s. no statistical significance. F Representative ERG waveform of mouse retina after SIO and/or Fer-1 treatment on day 14. G a- and b-wave amplitudes measured at 3 cd s/m² in mice receiving vehicle, SIO and/or Fer-1 injections. ODa a-wave in the right eye, ODb b-wave in the right eye, OSa a-wave in the left eye, OSB b-wave in the left eye. n = 6 (biological replicates). H a- and b-wave amplitudes measured at 10 cd s/m² in mice receiving vehicle, SIO and/or Fer-1 injection. n = 6 (biological replicates). *p < 0.05, **p < 0.01, ***p < 0.001.
20 μM for 6 h. As shown in Fig. 6A, the red fluorescence protein (RFP) signal indicated a successful transfection of cells by plasmids carrying both RFP and FSP1 DNA. In total, 70–80% of cells are expressing FSP1. A significantly increased FSP1 protein expression could also be observed in the transfected cells (Fig. 6B). As the concentration of SIO increases, cells transfected with vector DNA showed a sharp decrease in cell viability while FSP1-transfected cells exhibited a delayed decrease (Fig. 6C), suggesting a...
protective effect of FSP1 protein on SIO-challenged cells. The most significant difference in cell viability between vector + SIO group and FSP1 DNA + SIO group was observed when SIO concentration reached 5 μM (Fig. 6C). Therefore, this dosage was chosen in subsequent in vitro studies. Consistently, 5 μM SIO significantly decreased the viability of ARPE-19 cells transfected with vector control DNA (Fig. 6D) with noticeable cell morphological changes (Fig. 6E). However, this was ameliorated in ARPE-19 cells transfected with FSP1 DNA (Fig. 6D) that displayed less alteration of cell shape (Fig. 6E). 4-HNE staining also showed that
SIO-induced lipid peroxidation was markedly mitigated by FSP1 overexpression (Fig. 6F, G). In addition, while intracellular NADH level was significantly decreased in SIO-treated ARPE-19 cells transfected with vector control DNA, the decrease was more significant in FSP1-transfected ARPE-19 cells, suggesting that FSP1 might consume NADH in ARPE-19 cells (Fig. 6H). To further confirm this finding, NAD+/NADH assays were performed. SIO significantly increased the ratio of NAD+/NADH in ARPE-19 cells transfected with vector control DNA (Fig. 6I), and this was more evident in FSP1-transfected ARPE-19 cells, suggesting NADH consumption and subsequent generation of its metabolic product (NAD+). Moreover, intracellular CoQ10 was measured by ELISA assay. There was a significant decrease in SIO-treated ARPE-19 cells transfected with vector control DNA, and this was even more significant in FSP1-transfected ARPE-19 (Fig. 6J), which was consistent with the NADH result (Fig. 6H). In vivo data also showed that SIO administration significantly decreased the immunofluorescence intensity of FSP1 in different layers of the retina, suggesting impaired ferroptosis-defending ability (Fig. 7A, B). In contrast, SIO increased the fluorescence intensity of 4-HNE, which was widely distributed in various layers of the retina, indicating the presence of overwhelming retinal lipid peroxidation (Fig. 7A, C). In addition, SIO also significantly decreased the levels of NADH (Fig. 7D), and CoQ10 (ubiquinone) (Fig. 7F), but increased NAD+/NADH (Fig. 7E), which are the downstream markers of the FSP1-CoQ10-NADH pathway in ferroptosis. SIO also induced the loss of ZO-1 immunostained cells and increased 4-HNE immunofluorescence, indicating damage to tight junctions and RPE cells (Fig. 7A–C, p < 0.001), which is consistent with a recent study [29]. However, the destruction was alleviated by 14 days’ Fer-1 treatment (Fig. 7A–C, p > 0.001). These results further supported the involvement of ferroptosis in vivo. Overall, the evidence presented indicated that the FSP1-CoQ10-NADH pathway is involved in SIO-induced RPE degeneration and may play an important role in SIO-induced ferroptosis (Fig. 8).

**DISCUSSION**

We previously showed that amyloid-β oligomers-induced pyroptosis in APRE-19 cells [30] and proposed that novel RCD might contribute to a new concept on the pathogenesis of retinal diseases [31]. In this study, we clarified the likely role of ferroptosis associated with both GSH-GPx-4 and FSP1-CoQ10-NADH pathways in SIO-induced RPE degeneration pathogenesis. It has been shown that a higher level of iron was detected in post-mortem retinas with RPE degeneration when compared with controls [32]. Iron accumulation in the RPE also led to retinal degeneration with features of the RPE degeneration [29, 33]. Deferiprone, an iron chelator, is also shown to protect against retinal degeneration caused by light damage, sodium iodate, and the rd6 mutation [34]. Overall, our findings together with others suggest that imbalanced iron homeostasis and subsequent development of ferroptosis play a novel role in RPE degeneration (Fig. 8).

RCD, including necroptosis, pyroptosis, and ferroptosis in RPE cells has been shown to be involved in RPE degeneration pathogenesis [14, 20, 30]. Necroptosis in RPE cells was demonstrated in SIO-induced cell death and retinal damage [14]. The involvement of NLRP3-mediated pyroptosis in RPE cell death was identified in amyloid β oligomers-induced RPE degeneration models [30]. Besides, ferroptosis was shown in SIO-induced ARPE-19 cell damage in a recent study [35]. However, this study focused on the classical pathway of ferroptosis without a loss-of-function study such as GPx-4 knockdown. The authors mainly showed the protective effect of 24-h Fer-1 pre-treatment at 100 μM on ARPE-19 cells (an RPE cell line) upon SIO-induced damage. In contrast, we performed ferroptosis studies on primary HRPEpiC, ARPE-19 cell line, and mice using both pharmacological and loss-of-function strategies. We observed similar Fer-1 protective results on APRE-19 cells that were associated with the classical pathway of ferroptosis (GSH-GPx-4), but at a lower dosage after a shorter pre-treatment period. Fer-1 is a bioactive small molecule (molecular weight 262.35) classified as an antioxidant and cytoprotectant. It was identified as the first ferroptosis inhibitor and has been used in numerous in vitro and in vivo studies based on its efficacy in anti-lipid peroxidation in ferroptosis [36–40]. More importantly, we found that Fer-1 pre-treatment at 50 μM for 3 h effectively protected SIO-induced primary HRPEpiC cell death by decreasing MDA level. Based on these findings, we also discovered dramatic changes in subcellular level and in glutathione metabolisms when both types of RPE cells were exposed to SIO. We further investigated the role of the novel pathway of ferroptosis (FSP1-CoQ10-NADH) in SIO-induced RPE degeneration. Finally, we confirmed this phenomenon in vivo with a retinal function test ERG.

DFO is an FDA-approved iron-chelating agent for the treatment of acute iron intoxication and chronic iron overload. It chelates mostly Fe2+. It is also a representative inhibitor of ferroptosis and has been used extensively for various disease models [40]. However, due to DFO’s toxicity to the retina probably by inducing iron deficiency in the RPE, we did not perform in vivo study using DFO [41].

One of the limitations of this study is that the in vivo use of Fer-1 may not be recommended [16] due to the possible stability issues and short plasma half-life [42]. Fer-1 is a bioactive small molecule (molecular weight 262.35) classified as an antioxidant and cytoprotectant. It was identified as the first ferroptosis inhibitor and has been used in several in vitro and in vivo studies based on its efficacy in anti-lipid peroxidation in ferroptosis [36–40]. In our in vivo study, we chose a dosage of Fer-1 (2 mg/kg/day) that has been used in other in vivo studies [43–45]. We also performed daily administration of Fer-1, hoping that this may compensate for its short plasma half-life. In fact, we confirmed the protective effect of Fer-1 on RPE degeneration. As there was another report using Fer-1 in mice [46], we hoped that the use of the experimental animals in our study was well justified. Indeed, our animal data provided important in vivo evidence on the role of ferroptosis in RPE degeneration. Our in vivo results discovered a strong protective effect of Fer-1 on SIO-induced RPE degeneration, with significantly improved retinal thickness and function according to H&E staining results and ERG data. We next analyzed the involvement of the classical ferroptosis pathway in mouse RPE and found remarkable iron overload and impaired glutathione metabolism with increased lipid peroxidation. Based on these discoveries, we further investigated the association of a...
novel ferroptosis signaling and found that SIO-induced significant activation of the FSP1-CoQ10-NADH pathway in the RPE, which was reversed by Fer-1 treatment. We believe that these findings will contribute to the understanding of RPE degeneration pathology and to the development of new pharmacological agents. GPX4 and FSP1 are two independent pathways in ferroptosis in a variety of cell types [18]. Whether GPX4 or FSP1 overexpression could rescue iFSP1 or GPX4 siRNA phenotypes in RPE cells is also a way to validate the relationship of the two pathways in the future study.
In conclusion, our in vitro and in vivo studies demonstrated for the first time the involvement of the FSP1-CoQ10-NADH pathway in SIO-induced RPE degeneration, in addition to the classical GPx-4-GSH pathway. Inhibition or promotion of ferroptosis could rescue or aggravate RPE degeneration accordingly. This study provides important information for developing novel RPE degeneration therapies by targeting ferroptosis in the regulation of iron imbalance and lipid peroxidation.

**MATERIALS AND METHODS**

**Cell culture and chemical treatment**

Primary human retinal pigment epithelial cell (HRP-Epic) (Catalog#65440, Homp sapiens, ScienCell) and human adult retinal pigment epithelial cell line 19 (ARPE-19) (Homo sapiens, ATCC® CRL2302™) were obtained from ATCC. Primary HRP-Epic cells within three passages were cultured in T25 flasks coated with Poly-L-lysine with DMEM/F-12 (Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12) (12400-016, Gibco, Thermo Fisher Scientific, Waltham, Massachusetts, USA) medium containing 1% epithelial cell growth supplement (EpiCGS), 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). ARPE-19 cell culture work was performed as previously described [30]. Briefly, cells within ten passages were cultured in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (12400-016, Gibco, Thermo Fisher Scientific, Waltham, Massachusetts, USA) supplemented with FBS (10%) and 1% P/S/5% CO₂ at 37 °C.

For pre-treatment experiments, cells were seeded in a 12-well plate (5 × 10^4 cells/well) (665 180, Greiner-Bio, Kremsmünster, Austria) pre-treated with Fer-1 (0, 10, 25, 50, 100 μM, SML0583, Sigma Aldrich, Missouri, USA) or DFO (0, 5, 15, 25, 50 μM, D9533, Sigma Aldrich, Missouri, USA) for 3 h before subjecting them to sodium iodate (SIO, S4007, Sigma Aldrich, Missouri, USA) challenge for 24 h and harvested for analyses. The same concentration of DMSO and 1×PBS were used for the controls of Fer-1 and DFO, respectively. Ferroptosis suppressor protein 1 inhibitor at different concentrations (0, 1, 2, 5, 10 μM) (150651-39-1, MedChemExpress, Monmouth Junction, USA) were added to ARPE-19 cell culture medium for 24 h with or without subsequent treatment of SIO for 24 h.

**Assessment of cell viability**

Cell viability was evaluated by CCK-8 assay as reported [30]. Cells were seeded in 96-well plate (3 × 10^4 cells/well) (665 180, Greiner-Bio, Kremsmünster, Austria) pre-treated with Fer-1 (0, 10, 25, 50, 100 μM) or DFO (0, 5, 15, 25, 50 μM) for 3 h. Bright field images were obtained for assessment of morphological changes by TE2000 inverted microscopic imaging system (Nikon, Tokyo, Japan). IFSP1, an IFSP1 inhibitor was administrated to the ARPE-19 cells at different concentrations (μM) with or without SIO (20 μM) treatment. IFSP1 stock was dissolved in DMSO while SIO was dissolved in PBS. For the control normalization experiment, the following experiments were performed: (1) PBS + SIO - DMSO; (2) PBS + IFSP1; (3) SIO + IFSP1; (4) SIO + DMSO. The DMSO concentration present in each dosage of IFSP1 (0, 1, 2, 5, 10 μM) corresponded to 0%, 0.01%, 0.02%, 0.05%, 0.1%, respectively. In addition, PBS + IFSP1 + Fer-1 and SIO + IFSP1 + Fer-1 groups were supplemented to test if IFSP1 induces ferroptosis and not another kinds of cell death. ARPE-19 cells were pre-treated with 50 μM Fer-1 for 3 h before subjecting them to IFSP1 (0, 1, 2, 5, 10 μM or SIO (20 μM) for 24 h respectively, followed by the measurement of cell viability. Cell viability was also illustrated using LIVE/DEAD Cell Imaging Kit (488/570) (R37601, Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s instructions [47]. The cells were imaged by TE2000 inverted microscopic imaging system (Nikon, Tokyo, Japan).

**GFP-4 small interfering RNA and transfection**

Small interfering RNA (siRNA) targeting at GFP-4 (AM16708, Thermo Fisher Scientific, Waltham, Massachusetts, USA) and negative control siRNA (AM4611, Thermo Fisher Scientific, Waltham, Massachusetts, USA) were transfected into ARPE-19 cells using Lipofectamine 3000 (L3000001, Thermo Fisher Scientific, Waltham, Massachusetts, USA) and Opti-MEM™ I Reduced Serum Medium (31905070, Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to manufacturer’s instruction. Transfected cells were then cultured for 48–72 h at 37 °C and harvested for analysis. Transfection efficacy was evaluated by Western blotting to assess the expression of GFP-4.

**Animals**

In total, 6–8-week-old wildtype C57BL/6J male mice were obtained from a specific pathogen-free level animal facility at Centre for Comparative Medicine Research, The University of Hong Kong with 12 h light/dark cycle. The experimental procedures were approved by the Committee on the Use of Live Animals in Teaching and Research of The University of Hong Kong. For the establishment of RPE degeneration in vivo, mice received a single intraperitoneal injection of sodium iodate (SIO, S4007, Sigma Aldrich, Missouri, USA) dissolved in PBS at 30 mg/kg/day and 50 mg/kg/day. The extent of RPE damage was assessed and the RPE degeneration phenotype was successfully induced 3 days after a single intraperitoneal injection of SIO at 30 mg/kg. Therefore, in subsequent studies, mice were randomly divided into three groups: control group, SIO group, and Fer-1 group. Mice in the SIO group were given one SIO injection at 30 mg/kg (n = 6) on day 3. The optimized phenotype of RPE degeneration was confirmed 3 days after SIO injection. Therefore, mice in the Fer-1 group were treated daily with an intraperitoneal injection of Fer-1 (2 mg/kg/day in 2% DMSO in PBS, n = 6) starting at this time (Fig. 3A). Vehicle-treated animals received an equal volume of 2% DMSO in PBS (n = 6). On day 14, mice were sacrificed by pentobarbital overdose.

Mouse survival rate was estimated as follows. Survival rate on day N = 100% × (Total number of mice at the beginning of the experiment – dead number of mice from day 0 of the experiment)/Total number of mice at the beginning of the experiment. Body weight was monitored by daily weighing using a balance (PB-1200, Oriental Scales, Hong Kong). Daily IOP was measured by a portable rebound tonometer (Tonolab; Icare, Espoo, Finland) according to the manufacturer’s instruction. Briefly, the tonometer was handheld 1–2 mm in front of the mouse’s central cornea without anesthesia. A value was generated after automatic averaging of 6 consecutive tests by the tonometer. Three values of each eye were collected and averaged on day 14.

For animal sample collection and processing, mouse RPE/choroid was isolated from enucleated eyeballs as described previously [48]. In brief, after removal of the neural retina, the RPE/choroid was immersed in 200 μL protein lysis buffer for 1 h on ice with frequent gentle tapping to break the brownish RPE clumps. It was subsequently transferred to a new centrifuge tube and kept on ice for 30 min to release the RPE protein.

**Electroretinogram**

ERG is used to test electrical activity and responsiveness of the retina upon light stimulation [22]. Waveforms recorded are separated into two components: a-wave and the subsequent b-wave. The a-wave is generated
by photoreceptors while b-wave reflects the response from bipolar cells and other layers of the outer retina. ERG was therefore measured as reported [23–26] to reflect retinal function. Briefly, mice were dark-adapted for at least 12 h and anesthetized with ketamine (70 mg/kg, i.p.) and xylazine (7 mg/kg, i.p.). Pupils were dilated with 1% tropicamide (1% Mydriacyl, Alcon, Alcon-Couvreur, Belgium) and the cornea was anesthetized with 0.5% Alcaine (0.5% proparacaine hydrochloride, Alcon, Alcon-Couvreur, Belgium). ERG was recorded (Diagnosys, Bengaluru, India) using a gold contact lens electrode, a reference electrode, and a ground electrode at two intensities (3 cd s/m² and 10 cd s/m²). An ERG software (Epsion V5) was used to analyze the waveforms.

**Measurement of the iron level**

Intracellular iron levels in human primary HRPEpiC, ARPE-19 cells, and mouse RPE were measured by iron assay kit (ab83366, abcam, Cambridge, United Kingdom) as described previously [49]. In brief, proteins were harvested from cultured cells and mouse retina. After estimation of protein concentration, samples and iron standards were incubated with working reagents in a 96-well plate for 60 min at 37 °C. Absorbance at 593 nm was measured with a microplate reader (ELx800, BioTek, Hong Kong, China). The iron concentration of each sample was normalized with protein concentration.

**Assessment of malondialdehyde (MDA) level**

Intracellular MDA levels in human primary HRPEpiC, ARPE-19 cells, and mouse RPE were measured with an MDA detection kit (S0131S, Beyotime Biotechnology, Shanghai, China) following the manufacturer’s instructions. MDA concentration in the samples was determined according to the standard curve and normalized with the corresponding protein concentrations.

**Detection of GSH + GSSG/GSH level**

GSH + GSSG/GSH levels in human primary HRPEpiC, ARPE-19 cells, and mouse RPE were detected by GSH + GSSG/GSH Assay Kit (Colorimetric) (ab239709, abcam, Cambridge, United Kingdom) as described previously [50].
Total GSH, including GSH and GSSG was measured using GSH reductase to reduce GSSG in the samples, which subsequently was oxidized by 5,5′-dithio-bis (2-nitrobenzoic acid) (DTNB), thereby producing a yellowish product, 5′-thio-2-nitrobenzoic acid (TNB). Total GSH was determined by measuring the absorbance with a microplate reader (ELx800, BioTek, Hong Kong, China) at 412 nm. GSSG was determined by removing endogenous GSH with GSH scavenger, followed by oxidation of DTNB. The level of GSH was calculated by subtracting the content of GSSG from the total GSH. Sample protein concentrations measured were used for normalization of GSH + GSSG/ GSH level.

**Plasmid preparation**

The plasmids, pCDH-CMV-AIFM2-3Flag-tRFP-F2A-Neo and pCDH-CMV-MCS-SBP-tRFP-F2A-Neo-3Flag were obtained from Hanyi biology limited, Guangzhou, China. Both plasmids were firstly transformed into competent cells (18265017, Thermo Fisher Scientific, Waltham, Massachusetts, USA). The presence of RFP signal indicated a successful transfection of cells by plasmids carrying both RFP and FSP1 DNA. They were thawed on ice and placed in two chilled polypropylene tubes in 50 µl aliquots. In total, 1 µl of each plasmid was immersed in the 50 µl cells, added to competent cells and incubated for 30–40 min on ice, followed by heat shock at 42 °C for 2 min and then immediately chilled in ice for 1–2 min. The competent cells and plasmid mixture were added into 500 µl Super Optimal Broth (S.O.C) medium with constant shaking at 37 °C overnight. In total, 10 µl or 50 µl of the mixture was spread on a lysogeny broth plate supplemented with 100 µg/ml ampicillin. All plates were cultured upside down overnight at 37 °C. On the next day, lysogeny broth plates were examined. Single colonies were isolated and incubated in tubes containing 15 ml lysogeny broth with 100 µg/ml ampicillin with constant shaking at 37 °C overnight. The turbid tubes were then centrifuged at 4000 rpm for 10–15 min, followed by plasmid extraction using Purelink Quick Plasmid Miniprep kit (REF K210010, Invitrogen, Waltham, Massachusetts, USA).

**NAD/NADH assay**

NAD/NADH levels in ARPE-19 cells and mouse retina were detected using NAD/NADH assay kit (Colorimetric) (ab65348, abcam, Cambridge, United Kingdom) as described previously [51]. Cells or tissues were washed with cold PBS and harvested from 6-well plate. Cells or tissues were homogenized in NADH/NAD extraction buffer, followed with assay procedures according to kit instructions. Levels of NADH/NAD were calculated based on the standard curve.
The enzyme-linked immunosorbent assay (ELISA)
RPE cells were harvested and incubated with protein lysis buffer. After two free-thaw cycles, the homogenates were centrifuged, and the supernatant was assayed. Intracellular CoQ$_{10}$ (ubiquinone) was determined using CoQ$_{10}$ ELISA kit (EK33185, Biomatik, Ontario, Canada) following the manufacturer's instructions.

Retinal pigment epithelium/choroid flatmounts
C57BL/6J mice were sacrificed with pentobarbital overdose, and eyeballs were enucleated. The lens and the neuroretina were removed carefully. The RPE/choroid was flat-mounted on the glass slide, and examined by immunohistochemistry assays.

Immunohistochemistry
Cultured cells were fixed in 4% paraformaldehyde for 1 h and blocked with 5% goat serum with 0.5% Triton X-100. Eyeballs were collected and fixed in 4% paraformaldehyde in PBS for 1 h and embedded in paraffin. Five-μm thick cross-sections with the optic nerve stumps were blocked with 5% goat serum with 0.5% Triton X-100 for 1 h. Subsequently, cells and mouse retinal sections were incubated overnight at 4 °C with anti-Hyroxynymonal antibody (1:1000, MAS-27570, Invitrogen, Waltham, Massachusetts, USA) and anti-AMID antibody (B-6) (1:1000, sc-377120, Santa Cruz, CA, USA), followed by goat anti-mouse IgG H&L (Alexa Fluor® 488, 1:500, ab150113, Cambridge, United Kingdom). DAPI (1:1000, ab228549, abcam, Cambridge, United Kingdom) was used to stain the nuclei. A TE2000 inverted microscope imaging system (Nikon, Tokyo, Japan) was used to acquire fluorescence images. Five images were taken for each sample in all experimental groups, with duplicates in independent experiments. Image J was used to analyze the immunofluorescence intensity of all images obtained from each group after background subtraction. Representative images were presented.

Transmission electron microscope (TEM)
Cell morphology and mitochondria changes were examined by TEM. ARPE-19 cells with/without SIO challenge were trypsinized, washed with 1xPBS, and centrifuged. The cell pellets were resuspended in 4% paraformaldehyde, followed by epoxy resin embedding and staining with uranyl acetate and lead citrate. Samples were examined with a CM-100 TEM (Philips, Amsterdam, the Netherlands).

Western blotting
An equal amount of proteins was loaded into the polyacrylamide gel (12.5%) and transferred to polyvinylidene difluoride membranes. After blocking with 5% non-fat milk and 0.001% Tween-20 in Tris-buffered saline (1X TBSST) for 1 h, the membrane was first incubated with anti-GPX1 antibody (1:1000, sc-166120, Santa Cruz, CA, USA), anti-ACSL4 antibody (1:1000, sc-365230, Santa Cruz, CA, USA) and anti-AMID antibody (B-6) (1:1000, sc-377120, Santa Cruz, CA, USA) at 4 °C overnight followed by incubation with rabbit anti-mouse IgG H&L (Alexa Fluor® 488) (1:500, ab150117, abcam, Cambridge, United Kingdom) for 1 h at room temperature. Band visualization was performed by Amersham Imager 680 imager, and the intensity was analyzed by Image J.

Statistics
Experimental results were presented as mean ± standard error of the mean. Student’s t tests or one-way ANOVA followed by LSD test were used for data analysis using SPSS 20.0 software (SPSS Inc., Chicago, USA). p < 0.05 was considered statistically significant.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES
1. Chai K, Kitamura K, McCann A, Wu XR. The epithelium-molecular landscape for an interactive barrier. J Biomed Biotechnol. 2010;2010:870506.
2. Takahashi VKL, Takuji JT, Jauregui R, Tsang SH. Gene therapy in inherited retinal degenerative diseases, a review. Ophthalmic Genet. 2018:39:560–8.
3. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalomol. 2000;45:115–34.
4. Trachsel-Moncho L, Benilch-Narvarro S, Fernandez-Carbonell A, Ramirez-Lamelas DT, Olivar T, Silvestre D, et al. Oxidative stress and apoptosis-related changes during retinal degeneration and development. Cell Death Dis. 2018:9:121.
5. Benedetto MM, Cointin MA. Oxidative stress in retinal degeneration promoted by constant LED light. Front Cell Neurosci. 2019;13:139.
6. Mao H, Seo SJ, Biswal MR, Li H, Conners M, Nandyala Y, et al. Mitochondrial oxidative stress in the retinal pigment epithelium leads to localized retinal degeneration. Invest Ophthalomol Vis Sci. 2014;55:4613–27.
7. Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell. 2011;147:742–58.
8. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018:25:486–514.
9. Dai B, Lei C, Lin R, Tao L, Bin Y, Peng H, et al. Activation of Liver X receptor alpha protects amyloid beta1-40 induced inflammatory and senescent responses in human retinal pigment epithelial cells. Inflamm Res. 2017;66:523–34.
10. Masuda N, Tsujinaka H, Hirai H, Yamashita M, Ueda T, Ogata N. Effects of centration of amyloid beta (Abeta) on viability of cultured retinal pigment epithelial cells. BMC Ophthalomol. 2019:19:70.
11. Nilsson SE, Knave B, Persson HE. Changes in ultrastructure and function of the sheep pigment epithelium and retina induced by sodium iodate. II. Early Eff Acta Ophthalomol. 1977:55:1007–26.
12. Nilsson SE, Knave B, Persson HE. Changes in ultrastructure and function of the sheep pigment epithelium and retina induced by sodium iodate. III. Eff Delayed Eff Acta Ophthalomol. 1977:55:1027–43.
13. Nilsson SE, Knave B, Persson HE. Changes in ultrastructure and function of the sheep pigment epithelium and retina induced by sodium iodate. I. The ultrastructure of the normal pigment epithelium of the sheep. Acta Ophthalomol. 1977:55:994–1006.
14. Hanus J, Anderson C, Sarraf D, Ma J, Wang S. Retinal pigment epithelial cell necroptosis in response to sodium iodate. Cell Death Disc. 2016:2:16054.
15. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.
16. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266–82.
17. Kraft VAN, Bejzaj CT, Pfeiffer S, Ringelstetter L, Muller C, Zandkarimi F, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2020:6:41–53.
18. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693–8.
19. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688–92.
20. Totsuka K, Iwata T, Uchida T, Roggia MF, Nakagawa S, Vavvas DG, et al. Oxidative stress induces ferroptotic cell death in retinal pigment epithelial cells. Exp Eye Res. 2019;181:316–24.
21. Chowlers G, Cohen M, Marks-Ohana D, Stika S, Eijzenberg A, Banin E, et al. Course of sodium iodate-induced retinal degeneration in albino and pigmented mice. Invest Ophthalomol Vis Sci. 2017;58:2239–49.
22. Rossmiller BP, Ryals RC, Lewin AS. Gene therapy to rescue retinal degeneration caused by mutations in rhodopsin. Methods Mol Biol. 2015;1271:391–93.
23. Wang W, Tam KC, Ng TC, Goit RK, Chan KLS, Lo ACY. Long-term lutein administration attenuates retinal inflammation and functional deficits in early diabetic retinopathy using the Lmna(Akita/+/-) mice. BMJ Open Diabetes Res Care. 2020;8:e001519.
24. Yang D, So KF, Lo AC. Lycium barbarum polysaccharide extracts preserve retinal function and attenuate inner retinal neuronal damage in a mouse model of transient retinal ischaemia. Clin Exp Ophthalomol. 2017;45:577–29.
25. Li SY, Fung FK, Fu ZJ, Wong D, Chan HH, Lo AC. Anti-inflammatory effects of lutein in retinal ischemic/hypoxic injury: in vivo and in vitro studies. Invest Ophthalomol Vis Sci. 2012;53:5976–84.
26. Lelong DC, Bleche I, Perez E, Bigot K, Leempunt J, Laurendeau L, et al. Novel mouse model of monocular amaurosis fugax. Stroke. 2007;38:2337–44.
27. Selit TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 2019;133:144–52.
28. Beatty A, Singh T, Tyurina YY, Tyurin VA, Samovich S, Nicolas E, et al. Ferroptotic cell death triggered by conjugated linoleic acids is mediated by ACSL1. Nat Commun. 2021;12:2244.

29. Tang Z, Yu Y, Dai X, Ni N, Liu Y, Zhang D, et al. HO-1-mediated ferroptosis as a target for protection against retinal pigment epithelium degeneration. Redox Biol. 2021;43:101971.

30. Yang M, So KF, Lo ACY, Lam WC. The effect of lycium barbarum polysaccharides on pyroptosis-associated amyloid beta-40 oligomers-induced adult retinal pigment cell 19 cell damage. Int J Mol Sci. 2021;22:4658.

31. Yang M, So KF, Lam WC, Lo ACY. Novel programmed cell death as therapeutic targets in age-related macular degeneration? Int J Mol Sci. 2020;21:7729.

32. Hahn P, Milam AH, Duniafe SL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch’s membrane. Arch Ophthalmol. 2003;121:1099–105.

33. Hahn P, Qian Y, Dentechev T, Chen L, Bead J, Harris ZL, et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci USA. 2004;101:13850–5.

34. Hadziahmetovic M, Pajic M, Grieco S, Song Y, Song D, Li Y, et al. The oral iron chelator deferoxamine protects against retinal degeneration induced through diverse mechanisms. Transl Vis Sci Technol. 2012;1:7.

35. Liu B, Wang W, Shah A, Yu M, Liu Y, He L, et al. Sodium iodate induces ferroptosis in human retinal pigment epithelium ARPE-19 cells. Cell Death Dis. 2021;12:2230.

36. Wang H, An P, Xie E, Wu Q, Fang X, Gao H, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology. 2017;66:449–65.

37. Li Q, Han X, Lan X, Gao Y, Wan J, Durham F, et al. Inhibition of neuronal ferroptosis protects hemorrhagic brain. JCI Insight. 2017:2:e90777.

38. Qiang Z, Dong H, Xia Y, Chai D, Hu R, Jiang H. Nrf2 and STAT3 alleviates ferroptosis-mediated IRR-ALI by regulating SLC7A11. Oxid Med Cell Longev. 2020;2020:149682.

39. Mao XY, Zhou HH, Jin WL. Ferroptosis induction in pentylenetetrazole kindling and pilocarpine-induced epileptic seizures in mice. FrontNeurosci. 2019;13:721.

40. Liu P, Feng Y, Li H, Chen X, Wang G, Xu S, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cell Mol Biol Lett. 2020;25:10.

41. Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S. Deferoxamine Retinopathy Study G. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology. 2002;109:164–71.

42. Devisserch L, Van Collie S, Hofmans S, Van Rompaey D, Goossens K, Meul E, et al. Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy. J Med Chem. 2018;61:10126–40.

43. Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453–7.

44. Zhang X, Du L, Qiao Y, Zhang X, Zheng W, Wu Q, et al. Ferroptosis is governed by differential regulation of transcription in liver cancer. Redox Biol. 2019;24:101211.

45. Tonnus W, Meyer C, Steinebach C, Belavgeni A, von Massenhausen A, Gonzalez SLC. Cisplatin-induced retinal pigment epithelial cell ferroptosis by a Jak1-2/STAT1/SLC7A11 signaling pathway in age-related macular degeneration. FEBS J. 2021;289:1968–83.

46. Wong FSY, Tsang KK, Chu AMW, Chan BP, Yao KM, Lo ACY. Injectable cell-encapsulating composite alginate-collagen platform with inducible termination switch for safer ocular drug delivery. Biomaterials. 2019;210:53–67.

47. Wei H, Xu Z, Granado H, Wu A, Handa JT. An easy, rapid method to isolate RPE cell protein from the mouse eye. Exp Eye Res. 2016;145:450–5.

48. Elhassany AEM, Soliman E, Marie M, McGuire P, Gu P, ElSohly M, et al. Heme-dependent ER stress apoptosis: a mechanism for the selective toxicity of the dihydroartemisinin, NSC735847, in colorectal cancer cells. Front Oncol. 2020;10:956.

49. Recalde MD, Miguel CA, Noya-Riobo MV, Gonzalez SL, Villar ML, Coronel MF. Resveratrol exerts anti-oxidant and anti-inflammatory actions and prevents oxaliplatin-induced mechanical and thermal allodynia. Brain Res. 2020;1748:147079.

50. Coronas-Serna JM, Luche A, Rodriguez-Escudero M, Roussin M, Imbert PRC, Rodriguez-Escudero I, et al. The TIR-domain containing effectors BtpA and BtpB from Brucella abortus impact NAD metabolism. PLoS Pathog. 2020;16:e1007979.

ACKNOWLEDGEMENTS
The authors would like to thank Prof. Peter D. Adams (Sanford Burnham Prebys Medical Discovery Institute) for his generous guidance and suggestions on revision of this manuscript, the Faculty Core Facility, LKS Faculty of Medicine, The University of Hong Kong for providing the Al 680 machine and LSM 800 confocal microscopy and Electron Microscopy Unit, Queen Mary Hospital. This study was supported by Health and Medical Research Fund, the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region (05163526, 06171516) and General Research Fund, Research Grants Council, The Government of the Hong Kong Special Administrative Region (17112919) to ACYL; Albert Bing-Ching Young Professorship Endowment in Ophthalmology to WCL.

AUTHOR CONTRIBUTIONS
MY: conceptualization, data curation, formal analysis, investigation, methodology, validation, visualization, writing—original draft, writing—review and editing. MGT: investigation, methodology, validation. KMF: supervision. JKW: methodology. RKG: methodology, resources. K-FS: supervision, writing—review, and editing. WCL: funding acquisition, project administration, resources, supervision, writing—review, and editing. ACYL: conceptualization, data curation, formal analysis, investigation, methodology, project administration, supervision, validation, visualization, writing—original draft, writing—review and editing. All authors have read and agreed to the published version of the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-04924-4.

Correspondence and requests for materials should be addressed to Kwok-Fai So, Wei-Ching Lam or Amy Cheuk Yin Lo.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022, corrected publication 2024